Merck dumps osteoporosis drug on stroke risk
Merck & Co has now pulled the plug on its troubled late-stage osteoporosis candidate odanacatib after concluding that the drug’s benefit does not outweigh its risks.
Read More
Tag: odanacatib
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
